TY - JOUR T1 - Clinical, functional and laboratory assessment of treatment efficacy in COPD patients JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - P3619 AU - Ilona Baranova AU - Igor Leshchenko Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/P3619.abstract N2 - Scientists have been investigating surfactant protein D (SP-D) actively but data of plasma SP-D correlation with other parameters in chronic obstructive pulmonary disease (COPD) patients is not full.The aim: assessment of clinical, functional parameters and SP-D blood plasma level in moderate and severe COPD patients under the different pharmacologic therapy.Materials and methods: Males with moderate (n=38, age 60,6±10,2 yrs) and severe (n=42, age 61,2±7,2 yrs) COPD initially were taking formoterol (FORM)+ beclomethasone dipropionate (BDP) + tiotropium bromide (TB) for 24 weeks (1treatment stage), then - TB for 12 weeks (2 stage) and finally - TB + FORM for 12 weeks (3 stage).SGRQ-C and mMRC parameters, FEV1and SP-D in blood plasma were investigated at the end of every stage of treatment. Frequency of exacerbations was assessed during 48 weeks of the study. Control group was 34 healthy men (age 62,3±5,8 yrs).Results: in the patients with moderate COPD we observed spread of COPD symptoms (p<0,001), SP-D elevation in blood plasma (p=0,01) at the 2 stage compared with the 1 stage, postbronchodilator FEV1 redused compared with the 1 (p<0,001) and the 3 (p<0,001) stages. Frequency of exacerbations increased in severe COPD patients on the 2 and the 3 stages of therapy versus the 1 stage (p<0,05).The highest system anti-inflammatory effect was observed under 3-component therapy.Conclusion: Investigation findings give evidence that combination of long-acting inhaled bronchodilators provides clinical and functional efficacy in moderate COPD patients. Only 3-component therapy (TB, FORM, BDP) provides low SP-D level in blood plasma of moderate and severe COPD patients (p>0,05 compared with control group). ER -